Nightingale S D, Saletan S L, Swenson C E, Lawrence A J, Watson D A, Pilkiewicz F G, Silverman E G, Cal S X
Division of General Internal Medicine, University of Texas Southwestern Medical School, Dallas 75235-9103.
Antimicrob Agents Chemother. 1993 Sep;37(9):1869-72. doi: 10.1128/AAC.37.9.1869.
TLC G-65, a liposome-encapsulated gentamicin, was given intravenously twice weekly for 4 weeks to AIDS patients with Mycobacterium avium-M. intracellulare complex (MAC) bacteremia at 1.7 mg of gentamicin per kg of body weight per infusion (4 patients), 3.4 mg/kg (10 patients), and 5.1 mg/kg (7 patients). MAC colony counts in blood fell by 75% or more in all three groups (P < 0.005). Drug resistance did not emerge during the study period. Transient renal insufficiency developed in one patient; no other adverse effects were detected. Liposome-encapsulated gentamicin is a potential therapy for MAC infections in AIDS patients.
TLC G - 65是一种脂质体包裹的庆大霉素,对患有鸟分枝杆菌 - 胞内分枝杆菌复合体(MAC)菌血症的艾滋病患者,每周静脉注射两次,持续4周,每次输注的庆大霉素剂量为每千克体重1.7毫克(4例患者)、3.4毫克/千克(10例患者)和5.1毫克/千克(7例患者)。所有三组患者血液中的MAC菌落计数均下降了75%或更多(P < 0.005)。在研究期间未出现耐药性。1例患者出现短暂性肾功能不全;未检测到其他不良反应。脂质体包裹的庆大霉素是治疗艾滋病患者MAC感染的一种潜在疗法。